LGI1-Antibody Encephalitis clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
at UCSD UCSF
Our lead scientists for LGI1-Antibody Encephalitis research studies include Jeffrey Gelfand.
Last updated: